Literature DB >> 6161889

The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice.

A Vyakarnam, P J Lachmann, K Sikora.   

Abstract

The possibility of enhancing the antigenicity of tumour cells by chemically attaching purified protein derivative (PPD) of tubercle bacillus as an immunogenic carrier determinant into the tumour cell surface has been explored in these studies. It was observed that multiple immunizations with PPD-coupled tumour cells did potentiate a marked anti-rumour response even to tumours that were very weakly antigenic. Moreover, such immunizations could be used to retard the growth of tumours in previously unimmunized animals. An attempt has been made to elucidate the important factors involved when PPD heterogenized tumour cells are used for immunization.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6161889      PMCID: PMC1458088     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

Review 1.  Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

2.  Concanavalin A derivatives with altered biological activities.

Authors:  G R Gunther; J L Wang; I Yahara; B A Cunningham; G M Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

3.  Antigenic expression of a murine lymphoma during growth in vitro.

Authors:  M Cikes
Journal:  Nature       Date:  1970-02-14       Impact factor: 49.962

4.  Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene.

Authors:  M A Basombrío
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

5.  Inhibition of transplanted rat tumors by immunization with identical tumor cells infected with Friend virus.

Authors:  H Kobayashi; F Sendo; H Kaji; T Shirai; H Saito; N Takeichi; M Hosokawa; T Kodama
Journal:  J Natl Cancer Inst       Date:  1970-01       Impact factor: 13.506

6.  Host responses with solid tumors. I. Monocytic effector cells within rat sarcomas.

Authors:  J S Haskill; J W Proctor; Y Yamamura
Journal:  J Natl Cancer Inst       Date:  1975-02       Impact factor: 13.506

7.  Enhanced immunogenicity of chemically-coated syngeneic tumor cells.

Authors:  W J Martin; J R Wunderlich; F Fletcher; J K Inman
Journal:  Proc Natl Acad Sci U S A       Date:  1971-02       Impact factor: 11.205

8.  Expression of H-2 and Moloney leukemia virus-determined cell-surface antigens in synchronized cultures of a mouse cell line.

Authors:  M Cikes; S Friberg
Journal:  Proc Natl Acad Sci U S A       Date:  1971-03       Impact factor: 11.205

9.  Ligand-induced movement of lymphocyte membrane macromolecules. II. Mapping of surface moieties.

Authors:  M J Karnovsky; E R Unanue; M Leventhal
Journal:  J Exp Med       Date:  1972-10-01       Impact factor: 14.307

10.  Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus.

Authors:  J Lindenmann; P A Klein
Journal:  J Exp Med       Date:  1967-07-01       Impact factor: 14.307

View more
  5 in total

1.  The heterogenization of tumour cells with tuberculin. I. The coupling of tuberculin to cell surfaces using con-A as ligand.

Authors:  P J Lachmann; A Vyakarnam; K Sikora
Journal:  Immunology       Date:  1981-02       Impact factor: 7.397

2.  Purified protein derivative (PPD).

Authors:  P J Lachmann
Journal:  Springer Semin Immunopathol       Date:  1988

3.  Migration inhibition factor secreting human T-cell lines reactive to PPD: a study of their antigen specificity, MHC restriction and the use of Epstein-Barr virus-transformed B-cell lines as requirement for antigen-presenting cells.

Authors:  A Vyakarnam; P J Lachmann
Journal:  Immunology       Date:  1984-12       Impact factor: 7.397

Review 4.  Tumour immunology: a review.

Authors:  P J Lachmann
Journal:  J R Soc Med       Date:  1984-12       Impact factor: 5.344

5.  A preliminary trial of a novel form of active immunotherapy in squamous cell carcinoma of the lung.

Authors:  P J Lachmann; R M Grant; L S Freedman; K Sikora; N M Bleehen
Journal:  Br J Cancer       Date:  1985-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.